Featured Armistice Capital Holds Position in Immunovant as IMVT-1402 Approaches Its First Major TestBy News Team05/05/20260 In March 2025, Immunovant reported that batoclimab had met the primary endpoint in its Phase 3 myasthenia gravis trial. By…
